Do analysts recommend INGN or PAVM?

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,303.51%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, INGN or PAVM?

PAVmed has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.39 -$22.75M -$0.90 N/A PAVmed $70K 456.00 $400K -$16.05 N/A

Is INGN or PAVM more profitable?

Inogen has a net margin of -6.94% compared to PAVmed's net margin of -10,794.64%. Inogen's return on equity of -13.17% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% PAVmed -10,794.64% -126.43% -25.49%

Does the media favor INGN or PAVM?

In the previous week, Inogen had 1 more articles in the media than PAVmed. MarketBeat recorded 2 mentions for Inogen and 1 mentions for PAVmed. Inogen's average media sentiment score of 0.05 beat PAVmed's score of 0.00 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, PAVM or OWLT?

PAVmed has higher earnings, but lower revenue than Owlet. Owlet is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PAVmed $70K 456.00 $400K -$16.05 N/A Owlet $114.41M 1.33 -$39.68M -$0.75 N/A

Is PAVM or OWLT more profitable?

Owlet has a net margin of -8.61% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -10,794.64% -126.43% -25.49% Owlet -8.61% -601.24% -15.96%

Does the media refer more to PAVM or OWLT?

In the previous week, PAVmed and PAVmed both had 1 articles in the media. Owlet's average media sentiment score of 0.34 beat PAVmed's score of 0.00 indicating that Owlet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Owlet 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is PAVM or CNXU more profitable?

Conexeu Sciences has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Conexeu Sciences' return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -10,794.64% -126.43% -25.49% Conexeu Sciences N/A -200.20% -177.26%

Does the media prefer PAVM or CNXU?

In the previous week, PAVmed and PAVmed both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 0.97 beat PAVmed's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Conexeu Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PAVM or APYX more profitable?

Apyx Medical has a net margin of -14.78% compared to PAVmed's net margin of -10,794.64%. Apyx Medical's return on equity of -76.60% beat PAVmed's return on equity. Company Net Margins Return on Equity Return on Assets PAVmed -10,794.64% -126.43% -25.49% Apyx Medical -14.78% -76.60% -13.91%

Does the media favor PAVM or APYX?

In the previous week, PAVmed and PAVmed both had 1 articles in the media. PAVmed's average media sentiment score of 0.00 beat Apyx Medical's score of -0.57 indicating that PAVmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Apyx Medical 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Do analysts rate KEQU or PAVM?

PAVmed has a consensus price target of $56.00, suggesting a potential upside of 1,303.51%. Given PAVmed's higher possible upside, analysts clearly believe PAVmed is more favorable than Kewaunee Scientific. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor KEQU or PAVM?

In the previous week, Kewaunee Scientific had 3 more articles in the media than PAVmed. MarketBeat recorded 4 mentions for Kewaunee Scientific and 1 mentions for PAVmed. Kewaunee Scientific's average media sentiment score of 0.19 beat PAVmed's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kewaunee Scientific 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PAVmed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PAVmed (PAVM) Competitors

$3.99 -0.19 (-4.55%)

Closing price 09/23/2026 03:59 PM Eastern

Extended Trading

$4.05 +0.06 (+1.60%)

As of 09/23/2026 07:00 PM Eastern

Compare

PAVM vs. INGN, OWLT, CNXU, APYX, and KEQU

Should you buy PAVmed stock or one of its competitors? PAVmed's main competitors and comparable companies include Inogen (INGN), Owlet (OWLT), Conexeu Sciences (CNXU), Apyx Medical (APYX), and Kewaunee Scientific (KEQU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does PAVmed compare to Inogen?

Inogen (NASDAQ:INGN) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Inogen has a net margin of -6.94% compared to PAVmed's net margin of -10,794.64%. Inogen's return on equity of -13.17% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
PAVmed	-10,794.64%	-126.43%	-25.49%

In the previous week, Inogen had 1 more articles in the media than PAVmed. MarketBeat recorded 2 mentions for Inogen and 1 mentions for PAVmed. Inogen's average media sentiment score of 0.05 beat PAVmed's score of 0.00 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

PAVmed has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A
PAVmed	$70K	456.00	$400K	-$16.05	N/A

PAVmed has a consensus price target of $56.00, indicating a potential upside of 1,303.51%. Given PAVmed's higher probable upside, analysts plainly believe PAVmed is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Inogen has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, indicating that its stock price is 47% less volatile than the broader market.

89.9% of Inogen shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Inogen beats PAVmed on 11 of the 17 factors compared between the two stocks.

How does PAVmed compare to Owlet?

PAVmed (NASDAQ:PAVM) and Owlet (NYSE:OWLT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

PAVmed has higher earnings, but lower revenue than Owlet. Owlet is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	456.00	$400K	-$16.05	N/A
Owlet	$114.41M	1.33	-$39.68M	-$0.75	N/A

PAVmed currently has a consensus target price of $56.00, indicating a potential upside of 1,303.51%. Owlet has a consensus target price of $15.00, indicating a potential upside of 188.18%. Given PAVmed's higher probable upside, equities analysts plainly believe PAVmed is more favorable than Owlet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

19.9% of PAVmed shares are held by institutional investors. Comparatively, 72.6% of Owlet shares are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Comparatively, 36.2% of Owlet shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

PAVmed has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Owlet has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

In the previous week, PAVmed and PAVmed both had 1 articles in the media. Owlet's average media sentiment score of 0.34 beat PAVmed's score of 0.00 indicating that Owlet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Owlet	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Owlet has a net margin of -8.61% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Owlet	-8.61%	-601.24%	-15.96%

Summary

Owlet beats PAVmed on 10 of the 15 factors compared between the two stocks.

How does PAVmed compare to Conexeu Sciences?

PAVmed (NASDAQ:PAVM) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

PAVmed presently has a consensus price target of $56.00, suggesting a potential upside of 1,303.51%. Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 375.06%. Given PAVmed's higher probable upside, equities analysts plainly believe PAVmed is more favorable than Conexeu Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

19.9% of PAVmed shares are held by institutional investors. 13.4% of PAVmed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, PAVmed and PAVmed both had 1 articles in the media. Conexeu Sciences' average media sentiment score of 0.97 beat PAVmed's score of 0.00 indicating that Conexeu Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Conexeu Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Conexeu Sciences has a net margin of 0.00% compared to PAVmed's net margin of -10,794.64%. PAVmed's return on equity of -126.43% beat Conexeu Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Conexeu Sciences	N/A	-200.20%	-177.26%

PAVmed has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	456.00	$400K	-$16.05	N/A
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.40	N/A

Summary

PAVmed beats Conexeu Sciences on 8 of the 11 factors compared between the two stocks.

How does PAVmed compare to Apyx Medical?

PAVmed (NASDAQ:PAVM) and Apyx Medical (NASDAQ:APYX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Apyx Medical has a net margin of -14.78% compared to PAVmed's net margin of -10,794.64%. Apyx Medical's return on equity of -76.60% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PAVmed	-10,794.64%	-126.43%	-25.49%
Apyx Medical	-14.78%	-76.60%	-13.91%

PAVmed has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Apyx Medical has a beta of 1.31, suggesting that its share price is 31% more volatile than the broader market.

19.9% of PAVmed shares are held by institutional investors. Comparatively, 55.3% of Apyx Medical shares are held by institutional investors. 13.4% of PAVmed shares are held by company insiders. Comparatively, 15.9% of Apyx Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PAVmed currently has a consensus target price of $56.00, suggesting a potential upside of 1,303.51%. Apyx Medical has a consensus target price of $6.60, suggesting a potential upside of 123.73%. Given PAVmed's higher probable upside, equities research analysts plainly believe PAVmed is more favorable than Apyx Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

PAVmed has higher earnings, but lower revenue than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than PAVmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PAVmed	$70K	456.00	$400K	-$16.05	N/A
Apyx Medical	$58.42M	2.13	-$11.21M	-$0.20	N/A

In the previous week, PAVmed and PAVmed both had 1 articles in the media. PAVmed's average media sentiment score of 0.00 beat Apyx Medical's score of -0.57 indicating that PAVmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Apyx Medical	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Summary

Apyx Medical beats PAVmed on 11 of the 16 factors compared between the two stocks.

How does PAVmed compare to Kewaunee Scientific?

Kewaunee Scientific (NASDAQ:KEQU) and PAVmed (NASDAQ:PAVM) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, dividends, media sentiment, earnings, profitability, analyst recommendations, valuation and risk.

Kewaunee Scientific has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282M	0.35	$9.62M	$2.76	12.33
PAVmed	$70K	456.00	$400K	-$16.05	N/A

Kewaunee Scientific has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market.

PAVmed has a consensus price target of $56.00, suggesting a potential upside of 1,303.51%. Given PAVmed's higher possible upside, analysts clearly believe PAVmed is more favorable than Kewaunee Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
PAVmed	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Kewaunee Scientific had 3 more articles in the media than PAVmed. MarketBeat recorded 4 mentions for Kewaunee Scientific and 1 mentions for PAVmed. Kewaunee Scientific's average media sentiment score of 0.19 beat PAVmed's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kewaunee Scientific	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PAVmed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kewaunee Scientific has a net margin of 2.97% compared to PAVmed's net margin of -10,794.64%. Kewaunee Scientific's return on equity of 11.61% beat PAVmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	2.97%	11.61%	4.82%
PAVmed	-10,794.64%	-126.43%	-25.49%

32.7% of Kewaunee Scientific shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 14.1% of Kewaunee Scientific shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Kewaunee Scientific beats PAVmed on 12 of the 15 factors compared between the two stocks.

Get PAVmed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PAVM vs. The Competition

Export

Metric	PAVmed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$33.44M	$5.58B	$7.31B	$13.29B
Dividend Yield	N/A	1.79%	2.52%	12.57%
P/E Ratio	-0.25	25.26	274.07	25.69
Price / Sales	456.00	71.57	643.13	79.17
Price / Cash	N/A	33.02	77.80	52.76
Price / Book	-1.65	5.78	10.47	6.32
Net Income	$400K	$151.55M	$3.49B	$359.73M
7 Day Performance	0.50%	0.01%	-0.67%	0.17%
1 Month Performance	-21.76%	-3.51%	-3.17%	-3.27%
1 Year Performance	-69.76%	6.37%	15.13%	5.58%

PAVmed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PAVM PAVmed	2.3563 of 5 stars	$3.99 -4.5%	$56.00 +1,303.5%	-69.3%	$33.44M	$70K	N/A	41	Gap Down
INGN Inogen	0.7104 of 5 stars	$5.20 -0.6%	N/A	-39.0%	$138.80M	$348.67M	N/A	753	News Coverage
OWLT Owlet	2.4082 of 5 stars	$4.67 -1.0%	$15.00 +220.9%	-39.4%	$137.93M	$105.70M	N/A	114
CNXU Conexeu Sciences	2.4288 of 5 stars	$4.45 -11.0%	$20.00 +349.4%	N/A	$133.79M	N/A	N/A	4
APYX Apyx Medical	2.8907 of 5 stars	$2.96 -2.0%	$6.60 +123.0%	+41.1%	$127.21M	$52.84M	N/A	270	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PAVM) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PAVmed (PAVM) Competitors